Cipla USA, Inc. recalls Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactu…

Recall date

January 2, 2026

Source

U.S. Food & Drug Administration (FDA) — enforcement report

Recall number

D-0290-2026

FDA classification

Class II

Brand / firm

Cipla USA, Inc.

Sold / distributed

Nationwide in the USA

Why it was recalled

Presence of Particulate Matter.

Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What was recalled

Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67